119 results about "Assisted reproductive technology" patented technology

The subject invention relates to methods for improving a subject's vasculature to normalize maternal hemodynamics, particularly in subjects attempting to conceive via assisted reproductive technologies, and comprises increasing relaxin levels in a subject or increasing any one or more of: relaxin synthesis, relaxin receptor synthesis, relaxin binding to the relaxin receptor, or relaxin receptor activity.

The present invention relates to a method for determining the ideal time for and outcome of reproductive health procedures including in vitro fertilization by establishing a correlation between the successful outcome of said procedure and the spectra of a body fluid obtained using a chosen analytical modality for a population of patients, acquiring for a patient a spectrum of the body fluid of the patient using said chosen modality.

A container suitable for storing biological material which is laser etched with a two-dimensional bar code and methods for producing the same. The container can be in the form of a straw having a thickness between about 0.1 mm and about 0.3 mm or can be in the form of another container that holds multiple straws. The laser etched mark can be in the form of a two-dimensional bar code may be located on an exterior surface of the container, and when the container is a straw, it remains unwarped and impermeable to fluids.

Pharmaceutical compositions for treating male sub-fertility that include an agent that causes a reduction in an effect of extracellular DNA on sperm cells, are provided. The agent may be, for example, an enzyme that degrades DNA such as DNase, a substance that blocks the interaction between cell free DNA and sperm cell surface receptors, a substance that binds to DNA, a substance that inhibits endogenous sperm cell DNase, a substance that inhibits a member of a signal transduction pathway mediated by DNA binding to sperm cell surface receptors, or an agent that stimulates production of an endogenous substance that causes a reduction in an antifertility effect of cell free DNA on sperm cells. Also provided are methods for treating male sub-fertility by administering the pharmaceutical composition to a subject in need thereof. Further provided are methods for determining a fertility status in a male subject, methods for assisted reproduction, methods for selecting an assisted reproduction technique (ART), and methods for selecting sperm cells in a sperm cell population for use in an assisted reproduction technique.

This invention discloses a substantially protein-free cell culture solution for assisted reproductive technologies and methods of use thereof.

The invention relates to an extremely-low sperm freezing protective agent and application thereof. The protective agent is prepared from the following ingredients: sodium chloride, potassium chloride, magnesium sulfate, monopotassium phosphate, calcium chloride, fructose, trehalose, sodium citrate, glycin, glutamine, pentoxifylline, vitamin E, HAS (human serum albumin), glycerin and gentamicin sulphate. The extremely-low sperm freezing protective agent can protect less sperms with low activity and without forward activity ability in seminal fluid, can remarkably improve the activity ability of the sperms which swing weakly and cannot move forwards in seminal fluid after freezing and thawing, has no obvious influence on the physiological function of the sperms, has high freezing anabiosis rate, can be used for cryopreservation of less and weak sperms, testicle sperms and epididymis sperms, and contributes to the successful development of assisted reproductive technology.

The present invention relates to the use of an oxytocin receptor antagonist in females undergoing embryo transfer as part of an assisted reproductive technology. In particular, methods are provided for increasing ongoing implantation rate, increasing ongoing pregnancy rate, increasing clinical pregnancy rate, and / or increasing live birth rate in a female subject undergoing embryo transfer. Specifically, the antagonists are released in the luteal phase when the endometrium is receptive for embryo implantation and / or when the embryo has reached the blastocyst-stage.

The invention discloses a blastocyst nutrient solution and a preparation method thereof. The blastocyst nutrient solution comprises a composition for treating and culturing a zygote, a bactericide, a selectively added indicator and a selectively added human serum albumin. Each index of the blastocyst nutrient solution reaches the standard of an in-vitro nutrient solution, the use is safe, and whether the nutrient solution is deteriorated or not can be easily determined, and therefore a powerful guarantee is provided to the assisted reproductive technology.

The invention discloses an in-vitro maturation culture method for an oocyte mouse and a method for establishing a parthenogenetic embryonic stem cell line. In the in-vitro maturation culture method, an immature oocyte is cultured in a basic culture solution in which the HCG (human chorionic gonadotropin) and PMSG (pregnant mare serum gonadotropin) are added, and the maturation rate of the oocyte can reach more than 83 percent. In the method for establishing a parthenogenetic embryonic stem cell line, the parthenogenetic activation culture development is carried out on the mouse oocyte after in-vitro maturation culture to obtain the embryonic stem cell line; a hepatocyte obtained by the method has no immunogenicity, is simultaneously equivalent to a stem cell derived from a fertilized embryo on totipotency and has guiding significance for utilizing in-vitro maturation of the immature oocyte of a human and separating parthenogenetic embryonic stem cells. Aiming at the current conditionsof human ovum donation shortage, great discarding of clinical immature oocytes by an assisted reproductive technology, and the like, the two methods are combined to lay the foundation for developing and utilizing the in-vitro maturation culture of the immature oocyte of people and further researching the parthenogenetic embryo by utilizing an in-vitro mature ovum and separating the embryonic stemcells.

The invention relates to the field of genetic diagnosis and human assisted reproduction, and more particularly relates to an embryo pre-implantation genetic diagnosis technique (PGD). According to the method provided by the invention, for patients suffering from chromosomal balanced translocation (including reciprocal translocation and Robertson translocation) and mates thereof, family haplotype linkage analysis is performed on the chromosomes of the embryos obtained by in vitro fertilization and the relatives of the translocation carrier, the embryos with chromosomal balanced translocation and the embryos with normal chromosomes can be rapidly, simply and accurately distinguished, and at the same time, the chromosome copy number variation of the embryo is screened, so that the clinical pregnancy rate is improved, the genetic transmission of the chromosomal balanced translocation to the next generation is timely blocked before embryo implantation, and thus the development and progress of the human assisted reproductive technology are promoted to a certain extent.

The invention relates to a sperm washing liquid and a preparation method thereof and belongs to the technical field of human assisted reproduction. The sperm washing liquid is prepared by dissolving heparin sodium dry powder or heparin sodium salt solution in a salt solution containing antibiotics and indicator. Heparin sodium is added into the sperm washing liquid, and by combination with a receptor on the surface of sperm, heparin can activate a signal transduction system coupled with the receptor, so a capacity function of sperm mitochondria and calcium ion internal flow are improved mildly and effectively, sperm activity is improved, and not only can the artificial insemination success rate be improved, but also safety of the assisted reproductive technology is strongly ensured.

A 22 kD sperm protein, SP22, correlates with fertility and predicts fertility in males. The protein can be assayed to detect decreases in fertility resulting from exposure to toxicants and pollutants which are known or suspected to decrease fertility. In an antibody is generated to this protein, the antibody recognition by sperm in an epididymal sperm sample or ejaculate would reflect the fertility of the sample. This antibody can be used as a contraceptive to inactivate sperm, screen for toxicity, select animals for artificial insemination, and select men for assisted reproductive technologies. The protein itself can be inactivated by gene knockout, which is another approach to contraception, or the protein can be added to sperm from infertile men to make fertility techniques more feasible.

The invention discloses a protein extraction and treatment process at different time points (including early, middle and late periods of secretion: LH_2, LH_5, LH_7, LH_9, LH_10 and LH_12, and LH_0 on the day of injection of hCG) in a human endometrial tissue secretion period, and a protein spectrum and a phosphorylation modification mass spectrum are carried out to obtain molecular expression modes at different time points in the secretion period. The molecular expression modes can provide a basis for further knowing the dynamic change of the human endometrial tissue secretion period, and is beneficial to judging an endometrial implantation window period and guiding the embryo transplantation time in an assisted reproduction technology.

The invention discloses a sperm brake fluid and a preparation method thereof. The sperm brake fluid contains a combination, a fungicide and an indicator which carry out treatment on sperms. Each index of the sperm brake fluid disclosed by the invention is in compliance with the standards of an in-vitro culture solution, the sperm brake fluid is safe in use, and whether the culture solution is deteriorated is easily judged, thereby providing a powerful guarantee for an assisted reproductive technology.

The invention belongs to the technical field of assisted reproduction, and relates to an oocyte activating solution and application thereof. The oocyte activating solution comprises 1.1 to 1.8 mg / L ofionomycin, 6 to 12 mg / L of calcium ion carrier A23187, 63 to 94 mug / L of puromycin, 19 to 43 mg / L of 6DMAP, 3.4 to 6.6 mg / L of actinone CHX, 28 to 53 mug / L of phorbol PMA, 7.8 to 12.7 mug / L of inositol triphosphate, 1.5 to 2.4 g / L of SrCl2, 16 to 25 mg / L of heparin, and basic culture medium. The oocyte activating solution can effectively activate oocytes, and is suitable for activating the oocytes after ICSI in an in-vitro fertilization assisted reproduction technology.

The present invention relates to complement proteins, in particular, C3 protein, and methods using the same for enhancing the development of preimplantation mammalian embryos in vitro for use in assisted reproductive technologies. In particular, the present invention relates to supplementation of complement C3 protein, its precursors, fragments, or derivatives, to culture media to improve the development of cultured embryos and, thereby, enhance pregnancy rates of in vitro fertilization.

The present invention provides a method of predicting the probability of a successful pregnancy, either a naturally achieved pregnancy or a pregnancy resulting from an assisted reproductive technology, based on the level of L-selectin ligand expressed by uterine epithelial cells and / or the level of L-selectin expressed by an embryo in vitro. The invention further provides methods of inhibiting cell adhesion between a trophoblast and a uterine epithelial cell. Methods of inhibiting cell adhesion between a trophoblast and a uterine epithelial cell are useful to inhibit pregnancy. The invention further provides methods of assessing in vitro embryo quality. The invention further provides methods of predicting the probability of continued success of a pregnancy during the first 16 weeks of gestation.

The invention relates to the technical field of assisted reproduction, and discloses a cryoprotectant and an application thereof, a sperm refrigerating fluid and a preparation method of the sperm refrigerating fluid. The sperm refrigerating fluid comprises a cryoprotectant, a composition and a basic culture solution, wherein the cryoprotectant comprises 0.3 to 1.1 mg / L of paclitaxel, 16 to 22 g / Lof trehalose, 7 to 13 g / L of cane sugar and 80 to 250 mL / L of glycerinum; the composition comprises 12 to 26 mg / L of resveratrol, 0.2 to 1.9 mg / L of reduced glutathione, 436 to 775 mg / L of lecithin, 0.5 to 1.6 mg / L of cholesterol, 9 to 17 mg / L of ATP sodium salt, 11 to 28 mg / L of heparin, 93 to 299 mg / L of phosphatidylserine and 5 to 25 mg / L of coenzyme Q10. The sperm refrigerating fluid can reduce damage of sperms in low-temperature freezing and freezing resuscitation processes, improve vitality of the sperms after freezing resuscitation, prolong survival time of the sperms after freezing resuscitation, promote sperm capacitation and enhance penetrating fertilization capacity of the sperms to egg cells. Thus, the fertilization success rate and blastocyst formation rate of the ova are improved, and finally the effect of improving the pregnancy success rate of the in-vitro fertilization assisted reproduction technology is achieved.

A disposable polymer container for manipulation of small specimens adapted to optimize heat transfer between an external heating element and specimens herein contained. In particular, this invention relates to the field of containers for Assisted Reproductive Technology hereunder In-vitro fertilization (IVF).

The invention provides a human sperm cryopreservation liquid, a human sperm cryopreservation method, and a human sperm cryopreservation and recovery method. The cryopreservation liquid comprises a yolk liquid, glycerol, antibiotics, a refrigeration buffer solution, and quercetin or derivative thereof. The human sperm cryopreservation and recovery method comprises the steps of using the human sperm cryopreservation liquid, performing cold balance at a temperature of 4 DEG C, and then performing refrigeration at a temperature of minus 80 DEG C, and next, transferring to a liquid nitrogen tank for cryopreservation; and performing unfreezing and recovering in a water bath box at a temperature of 37 DEG C before use. The sperm cryopreservation liquid, added with the quercetin at a proper concentration, can effectively protect sperms and can remarkably improve survival rate and motility of revived sperms in the subsequent sperm recovery process, so that occurrence of sperm ROS and apoptosis can be reduced; and therefore, the human sperm cryopreservation liquid has application potential in the assisted reproductive technology.

The invention relates to a cleavage culture solution and a preparation method thereof and belongs to the technical field of human assisted reproductive technology. The cleavage culture solution has the advantages that the cleavage culture solution is prepared by adding alanine, aspartic acid, asparagine, glutamic acid, glutamine, glycine, proline, taurine, serine, threonine, tyrosine, methionine,lipoic acid, hyaluronic acid and a chelating agent into a salt solution, the activity and nutrition of an embryo can be kept effectively, the chelating agent can chelate some unnecessary heavy metal ions, the toxicity of the culture solution is lowered, the development of the early embryo can be promoted favorably, the success rate of the assisted reproductive technology is increased, and powerfulguarantee is provided for the safety of the assisted reproductive technology.

The invention relates to a sperm freezing fluid and a preparation method thereof and belongs to the technical field of human assisted reproduction. The sperm freezing fluid is prepared by dissolving glycerinum into a salt solution with cane sugar, antibiotics and an indication agent in a concentration of 20-30%. Due to addition of the glycerinum and the cane sugar in the sperm freezing fluid provided by the invention, the glycerinum and the cane sugar are adopted as cell protection agents which can not only gently and effectively protect activity of sperms and completeness of DNA (Deoxyribonucleic Acid), but also protect the activity of testicular tissue cells, furthermore the activity of sperms in testicular testes is protected, the fertility rate of the sperms is increased, and the security of assisted reproductive technologies is powerfully ensured.

The invention discloses an improved method and a kit for detecting quality of an assisted reproductive technology by a mouse embryo array, and particularly relates to a method for detecting the quality of the assisted reproductive technology (ART) by utilizing cell number at each stage of mouse embryo development and UTF1 positive cell number expressed by blastocyst in the mouse embryo assay (MEA), belonging to the technical field of cytology and biology. At present, based on the internationally common standard MEA, the following two standards are increased: (1) total number of cells contained in embryo at each 12-hour embryonic development period; (2) number of UTF1 positive cells expressed by the blastocyst and number of CDX2 cells expressed by trophoblast cell as well as a proportion of the UTF1 positive cells and the CDX2 cells to total cells of the blastocyst. By comparing the two standards for in-vitro cultivated and developed embryo with the in-vivo embryo at the corresponding period, relatively sensitive and effective means are provided for quality control, including optimizing in-vitro culture conditions and optimizing embryo culture liquor, of the detected assisted reproductive technology, and reference standards are provided for improving the assisted reproductive technology.

The present invention relates to culture media for oocytes and uses thereof. Specifically, media for culturing an oocyte in vitro are disclosed, wherein said media comprise granulocyte macrophage-colony stimulating factor (GM-CSF). The presence of GM-CSF in the media increases the maturation and / or developmental competence of the oocyte making it suitable for use in subsequent assisted reproductive technologies. Methods for increasing the maturation and / or developmental competence of an oocyte are also disclosed.

The invention relates to a mouse denuded oocyte (DO) in vitro maturation technology, belonging to the technical field of biology. The invention is characterized in that a cumulus cell uses cystine and cysteamine to improve GSH synthesis and developmental capacities of the DO and, through cumulus cell co-culture and addition of cysteamine and cystine, an in vitro maturation system is established, which completely recovers the developmental capacity of the DO. The DO is co-cultured with mouse or goat cumulus cells in TCM-199 mature culture fluid added with 100-200 mumol / l of cysteamine and 250-300 mumol / l of cystine, the blastocyst rate reaches the level of mature COC cultured by adding the same mercapto-compound. After transplanting 2-cell embryos from the mature DO through co-culture and from COC respectively, the differences in pregnancy rate and number born are not obvious. The invention, for the first time in the world, establishes an in vitro mature system for completely recovering the developmental capacity of mouse denuded oocyte, which is of great importance in the research and application of both animal embryo engineering and human-assisted reproductive technology.

A disposable polymer container for manipulation of small specimens adapted to optimize heat transfer between an external heating element and specimens herein contained. In particular, this invention relates to the field of containers for Assisted Reproductive Technology hereunder In-vitro fertilization (IVF).

The invention provides novel non-invasive in vitro methods for assessing the metabolic condition of oocytes and / or embryos with fluorescence lifetime imaging microscope, that can be used, for example, in assessment of oocytes and embryos in assisted reproductive technologies.